Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects.

BACKGROUND Information regarding the safety of selective serotonin-reuptake inhibitors (SSRIs) in human pregnancy is sparse. Concern has been raised about the risk of congenital heart defects associated with the use of SSRIs in pregnancy. METHODS We obtained data on 9622 case infants with major birth defects and 4092 control infants born from 1997 through 2002 from the National Birth Defects Prevention Study. Case infants were ascertained through birth-defects surveillance systems in eight U.S. states; controls were selected randomly from the same geographic areas. Mothers completed a standardized telephone interview regarding exposure to potential risk factors, including medications, before and during pregnancy. Exposure to SSRIs was defined as treatment with any SSRI from 1 month before to 3 months after conception. Birth defects were assigned to 26 categories and subcategories. RESULTS There were no significant associations between maternal use of SSRIs overall during early pregnancy and congenital heart defects or most other categories or subcategories of birth defects. Maternal SSRI use was associated with anencephaly (214 infants, 9 exposed; adjusted odds ratio, 2.4; 95% confidence interval [CI], 1.1 to 5.1), craniosynostosis (432 infants, 24 exposed; adjusted odds ratio, 2.5; 95% CI, 1.5 to 4.0), and omphalocele (181 infants, 11 exposed; adjusted odds ratio, 2.8; 95% CI, 1.3 to 5.7). CONCLUSIONS Maternal use of SSRIs during early pregnancy was not associated with significantly increased risks of congenital heart defects or of most other categories of birth defects. Associations were observed between SSRI use and three types of birth defects, but the absolute risks were small, and these observations require confirmation by other studies.

[1]  G. Shaw,et al.  Maternal Obesity, Gestational Diabetes, and Central Nervous System Birth Defects , 2005 .

[2]  J. Carey,et al.  The OEIS complex (omphalocele, exstrophy, imperforate anus, spinal defects). , 1978, Birth defects original article series.

[3]  S. Rasmussen,et al.  Maternal obesity and risk for birth defects. , 2003, Pediatrics.

[4]  L D Edmonds,et al.  The National Birth Defects Prevention Study , 2001, Public health reports.

[5]  B. Källén,et al.  Delivery outcome after the use of antidepressants in early pregnancy , 1999, European Journal of Clinical Pharmacology.

[6]  W. Daniel.  Mechanisms of cellular distribution of psychotropic drugs. Significance for drug action and interactions , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[7]  Orr St,et al.  Maternal Depressive Symptoms and the Risk of Poor Pregnancy Outcome Review of the Literature and Preliminary Findings , 1995 .

[8]  K. Ormond,et al.  Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. , 1998, JAMA.

[9]  J. K. Markham,et al.  Developmental Toxicology Studies of Fluoxetine Hydrochloride Administered Orally to Rats and Rabbits , 1994 .

[10]  P. Neuvonen,et al.  Risks Associated With Selective Serotonin Reuptake Inhibitors in Pregnancy , 2005, Obstetrics and gynecology.

[11]  J. Lauder,et al.  Serotonin and cardiac morphogenesis in the mouse embryo. , 1993, Teratology.

[12]  K. Rothman,et al.  A Prospective Study of the Risk of Congenital Defects Associated with Maternal Obesity and Diabetes Mellitus , 2000, Epidemiology.

[13]  P. Hallberg,et al.  Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn. , 2006, The New England journal of medicine.

[14]  S Lemeshow,et al.  Confidence interval estimation of interaction. , 1992, Epidemiology.

[15]  B. Källén,et al.  Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. , 2007, Birth defects research. Part A, Clinical and molecular teratology.

[16]  J. Lauder,et al.  Serotonin and morphogenesis , 2004, Anatomy and Embryology.

[17]  G. Koren,et al.  Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac) , 1993, JAMA.

[18]  Y. Sari,et al.  Serotonin and its transporter on proliferation of fetal heart cells , 2003, International Journal of Developmental Neuroscience.

[19]  H. Sørensen,et al.  Maternal Use of Selective Serotonin Reuptake Inhibitors and Risk of Congenital Malformations , 2006, Epidemiology.

[20]  R. Davis,et al.  Outcomes of prenatal antidepressant exposure. , 2002, The American journal of psychiatry.

[21]  S. Hernández-Díaz,et al.  First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. , 2007, The New England journal of medicine.

[22]  H. Flynn,et al.  Depressive symptoms among pregnant women screened in obstetrics settings. , 2003, Journal of women's health.

[23]  S. Rasmussen,et al.  Guidelines for case classification for the National Birth Defects Prevention Study. , 2003, Birth defects research. Part A, Clinical and molecular teratology.

[24]  B. Lester,et al.  The Effects of Maternal Depression on Fetal Heart Rate Response to Vibroacoustic Stimulation , 2001, Developmental neuropsychology.

[25]  K. Jones,et al.  Birth outcomes in pregnant women taking fluoxetine. , 1996, The New England journal of medicine.

[26]  P. Wadhwa,et al.  The association between prenatal stress and infant birth weight and gestational age at birth: a prospective investigation. , 1993, American journal of obstetrics and gynecology.

[27]  B. Källén,et al.  Antidepressant drugs during pregnancy and infant congenital heart defect. , 2006, Reproductive toxicology.

[28]  J. Mann,et al.  The medical management of depression. , 2005, The New England journal of medicine.

[29]  Lucie Blais,et al.  First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. , 2007, Birth defects research. Part B, Developmental and reproductive toxicology.

[30]  E. Frank,et al.  Pharmacologic treatment of depression during pregnancy. , 1999, JAMA.

[31]  C. Walker,et al.  Association between maternal obesity and fetal cardiac malformations in African Americans. , 2002, Journal of the National Medical Association.